These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16945077)

  • 1. A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients.
    Busti AJ; Tsikouris JP; Peeters MJ; Das SR; Canham RM; Abdullah SM; Margolis DM
    HIV Med; 2006 Jul; 7(5):317-22. PubMed ID: 16945077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir.
    Gianotti N; Guffanti M; Galli L; Margonato A; Chiaravalli G; Bigoloni A; Lazzarin A; Castagna A
    AIDS; 2007 Jul; 21(12):1648-51. PubMed ID: 17630564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
    Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
    Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
    J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
    Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
    Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atazanavir for treatment of HIV infection in clinical routine: efficacy, pharmacokinetics and safety.
    Feldt T; Oette M; Kroidl A; Göbels K; Leidel R; Sagir A; Kuschak D; Häussinger D
    Eur J Med Res; 2005 Jan; 10(1):7-10. PubMed ID: 15737947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects.
    Marbury TC; Jin B; Panebianco D; Murphy MG; Sun H; Evans JK; Han TH; Constanzer ML; Dru J; Shadle CR
    Anesth Analg; 2009 Aug; 109(2):418-25. PubMed ID: 19608812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
    Moltó J; Santos JR; Valle M; Miranda C; Miranda J; Blanco A; Negredo E; Clotet B
    Ther Drug Monit; 2007 Oct; 29(5):648-51. PubMed ID: 17898658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy.
    Hamada Y; Nishijima T; Watanabe K; Komatsu H; Tsukada K; Teruya K; Gatanaga H; Kikuchi Y; Oka S
    Clin Infect Dis; 2012 Nov; 55(9):1262-9. PubMed ID: 22820542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.
    Vergani B; Cicero ML; Vigano' O; Sirianni F; Ferramosca S; Vitiello P; Di Vincenzo P; Pia De Pasquale M; Galli M; Rusconi S
    J Clin Virol; 2008 Feb; 41(2):154-9. PubMed ID: 18024202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacology, efficacy and safety of atazanavir: a review.
    Bentué-Ferrer D; Arvieux C; Tribut O; Ruffault A; Bellissant E
    Expert Opin Drug Metab Toxicol; 2009 Nov; 5(11):1455-68. PubMed ID: 19863454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure.
    Vrtovec B; Okrajsek R; Golicnik A; Ferjan M; Starc V; Radovancevic B
    J Card Fail; 2005 Dec; 11(9):684-90. PubMed ID: 16360963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Literature review and pilot studies of the effect of QT correction formulas on reported beta2-agonist-induced QTc prolongation.
    Milic M; Bao X; Rizos D; Liu F; Ziegler MG
    Clin Ther; 2006 Apr; 28(4):582-90. PubMed ID: 16750469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.
    Luber AD; Brower R; Kim D; Silverman R; Peloquin CA; Frank I
    HIV Med; 2007 Oct; 8(7):457-64. PubMed ID: 17760738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study.
    Keiser PH; Nassar N
    Int J STD AIDS; 2008 Aug; 19(8):561-2. PubMed ID: 18663047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients.
    Galetta F; Franzoni F; Cervetti G; Cecconi N; Carpi A; Petrini M; Santoro G
    Biomed Pharmacother; 2005 Dec; 59(10):541-4. PubMed ID: 16325366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of HIV protease inhibitors on cardiac conduction velocity in unselected HIV-infected patients.
    Charbit B; Gayat E; Voiriot P; Boccara F; Girard PM; Funck-Brentano C
    Clin Pharmacol Ther; 2011 Sep; 90(3):442-8. PubMed ID: 21814195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies.
    Sarapa N; Nickens DJ; Raber SR; Reynolds RR; Amantea MA
    Clin Pharmacol Ther; 2008 Jan; 83(1):153-9. PubMed ID: 17581594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.